ZZZhiyao Zhou

Zhiyao Zhou

*This is an algorithmically generated author record based on publicly available information.

Zhiyao Zhou has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synthetic Approaches to the New Drugs Approved During 2024

    by Scott P. France, Erick A. Lindsey, Emma L. McInturff, Simon Berritt, Andrew C. Flick, Sarah Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, et al.

    In 2024, thirty-nine new small molecule drugs were approved worldwide. A brief introduction to each new drug is followed by the synthetic details that highlight the most scalable routes available at the time of publication in patents or primary literature. Structural complexity varies widely across the drugs that are included in the review, as do the methods of synthesis used to access these new drugs.


  • Cobalt-Catalyzed Asymmetric Cyclopropanation of Heteroaryl Alkenes with Homogeneous Zinc Carbenoids

    by Madeleine C. Deem, Dan Lehnherr, Tao Wang, Xiao Wang, Yu-Hong Lam, Steven M. Silverman, Justin A. Newman, Qiao Lin, Eric M. Phillips, Melodie Christensen, et al.

    Heteroaryl-functionalized chiral cyclopropanes are commonly found in pharmaceutically relevant molecules, yet their synthesis through catalytic asymmetric cyclopropanation presents multifaceted challenges concerning enantioselectivity, safety, and scalability. Herein, we report a homogeneous catalytic asymmetric cyclopropanation method by merging chiral pyridine bis-oxazoline (PyBox)-cobalt catalysts with readily accessible zinc carbenoids. This method enables facile access to chiral cyclopropanes bearing pyridyl, pyrimidyl, and other nitrogen-containing heterocyclic substituents with high enantioselectivities. Mechanistic studies support the direct transmetalation of the zinc carbenoid to the cobalt catalyst which then participates in cyclopropanation through a redox-neutral CoII catalytic cycle. The high enantioselectivity, homogeneity, and compatibility with various green solvents render this method amenable to scale up and application across diverse heteroaryl substrates.


  • Open Access

    Cobalt-Catalyzed Asymmetric Cyclopropanation of Heteroaryl Alkenes with Homogeneous Zinc Carbenoids

    by Madeleine C Deem, Dan Lehnherr, Tao Wang, Xiao Wang, Yu-Hong Lam, Steven M Silverman, Justin A Newman, Qiao Lin, Eric M Phillips, Melodie Christensen, et al.

    Heteroaryl-functionalized chiral cyclopropanes are commonly found in pharmaceutically relevant molecules, yet their synthesis through catalytic asymmetric cyclopropanation presents multifaceted challenges concerning enantioselectivity, safety, and scalability. Herein, we report a homogeneous catalytic asymmetric cyclopropanation method by merging chiral pyridine bis-oxazoline (PyBox)-cobalt catalysts with readily accessible zinc carbenoids. This method enables facile access to chiral cyclopropanes bearing pyridyl, pyrimidyl, and other nitrogen-containing heterocyclic substituents with high enantioselectivities. Mechanistic studies support the direct transmetallation of the zinc carbenoid to the cobalt catalyst which then participates in cyclopropanation through a redoxneutral Co II catalytic cycle. The high enantioselectivity, homogeneity, and compatibility with various green solvents render this method amenable to scale up and application across diverse heteroaryl substrates.

  • Divergent Total Synthesis of the Harziane Diterpenoids

    by Philipp M. Gemmel, Sohee Kim, Zhiyao Zhou, Justin R. Bossenbroek, Noel Cercizi, Scott A. Snyder

    The harziane family of diterpenoid natural products possesses a stereochemically dense 6/5/7/4 tetracyclic framework that is structurally distinct among secondary metabolites. Indeed, members contain up to six contiguous stereocenters, three all-carbon quaternary centers, and an array of differential oxidation patterns across the nearly 50 members that have been isolated since the inaugural member was first reported in 1992. Herein we report a concise strategy, guided both by quaternary center analysis as well as common intermediate logic, that has led to the synthesis of three family members with distinctive stereochemical and oxidation patterns as well as the proposed structure of a fourth; all were accessed in just 1-3 steps from that common, late-stage intermediate, and three of these structures have been prepared for the first time. Four other natural products were obtained formally from that same material. Key operations include (1) a Au(I)-catalyzed cycloisomerization reaction to forge their unique bicyclo[5.2.0]nonane framework, (2) a strategic semi-Pinacol ring contraction that sets the stage for formation of the final ring system, and (3) a suite of late-stage site- and chemo-selective redox reactions using synthetic handles on two different halves of the molecule that, when properly orchestrated, smoothly complete the targets.


  • Synthetic Approaches to the New Drugs Approved during 2023

    by Scott P. France, Erick A. Lindsey, Emma L. McInturff, Simon Berritt, Jacob DeForest, Andrew C. Flick, Sarah Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, et al.

    This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug's mechanism of action, the history of its discovery and development, and the synthetic approaches published in primary or patent literature that were most likely used for clinical studies or development are included. Synthetic chemistry, used to convert complex intermediates to active compounds or build a new drug from basic building block chemicals, is critical to delivery of new drugs and treatments for disease to patients.


  • Atactic, Isotactic, and Syndiotactic Methylated Polyhydroxybutyrates: An Unexpected Series of Isomorphic Polymers

    by Zhiyao Zhou, Anne M. LaPointe, Geoffrey W. Coates

    Polyhydroxyalkanoates (PHAs), such as poly[(R)-3-hydroxybutyrates] [(R)-P3HB], are produced by bacteria and are promising alternatives to nondegradable polyolefin plastics, but their semicrystallinity and high melting points are only maintained at high tacticity, which are commonly seen in other semicrystalline polymers like isotactic polypropylene (iPP). We herein report a class of synthetic PHAs, cis-poly(3-hydroxy-2-methylbutyrate)s (cis-PHMBs), that exhibit tacticity-independent semicrystallinity. The syndiotactic, isotactic, and even atactic PHMBs all share high melting points (Tm > 170 °C) and nearly identical crystal structures. The isomorphism of these polymers across three different tacticities has allowed access to iPP-like, high-performance PHMB without the requirement of high tacticity.


  • Nature-inspired methylated polyhydroxybutyrates from C1 and C4 feedstocks

    by Zhiyao Zhou, Anne M. LaPointe, Timothy D. Shaffer, Geoffrey W. Coates

    Polyolefin plastics are widely used due to their low cost and outstanding properties, but their environmental persistence presents a major societal challenge. Polyhydroxyalkanoates (PHA) are biodegradable substitutes for polyolefins, but their high cost and thermal instability are impediments to their widespread application. Here we report a series of methylated polyhydroxybutyrates, poly(3-hydroxy-2-methylbutyrate)s, which are structurally inspired by natural PHAs. The cis homopolymers exhibit tacticity-independent crystallinity, which allows for the discovery of high-melting, thermally stable and mechanically tough copolymers, and a full range of polyolefin-like properties can be further achieved by tailoring the cis/trans ratio of the repeating units. Moreover, these materials can be synthesized from inexpensive carbon monoxide and 2-butene feedstocks, and they can be chemically recycled or upcycled at their end of life. The versatile properties, abundant feedstocks and end-of-life utility of this family of polyesters will enable a powerful platform for the discovery of sustainable alternatives to polyolefin plastics.


  • Highly Selective Hydrogenation of C═C Bonds Catalyzed by a Rhodium Hydride

    by Yiting Gu, Jack R. Norton, Farbod Salahi, Vladislav G. Lisnyak, Zhiyao Zhou, Scott A. Snyder

    Under mild conditions (room temperature, 80 psi of H2) Cp*Rh(2-(2-pyridyl)phenyl)H catalyzes the selective hydrogenation of the C═C bond in α,β-unsaturated carbonyl compounds, including natural product precursors with bulky substituents in the β position and substrates possessing an array of additional functional groups. It also catalyzes the hydrogenation of many isolated double bonds. Mechanistic studies reveal that no radical intermediates are involved, and the catalyst appears to be homogeneous, thereby affording important complementarity to existing protocols for similar hydrogenation processes.


  • Top Cited Papers
    Open Access

    Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

    by Jerzy Osipiuk, Saara-Anne Azizi, Steve Dvorkin, Michael Endres, Robert Jedrzejczak, Krysten A. Jones, Soowon Kang, Rahul S. Kathayat, Youngchang Kim, Vladislav G. Lisnyak, et al.

    The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals. PLpro is an attractive target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses. We report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the SARS-CoV-2 enzyme. We determined the high resolution structure of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors. This collection of structures details inhibitors recognition and interactions providing fundamental molecular and mechanistic insight into PLpro. All compounds inhibit the peptidase activity of PLpro in vitro, some block SARS-CoV-2 replication in cell culture assays. These findings will accelerate structure-based drug design efforts targeting PLpro to identify high-affinity inhibitors of clinical value.


  • A Concise Total Synthesis of (+)‐Waihoensene Guided by Quaternary Center Analysis

    by Cheng Peng, Piyush Arya, Zhiyao Zhou, Scott A. Snyder

    The four contiguous all‐carbon quaternary centers of waihoensene, coupled with the absence of any traditional reactive functional groups other than a single alkene, render it a particularly challenging synthetic target among angular triquinane natural products. Here, we show that its polycyclic frame can be assembled concisely by using a strategically chosen quaternary center to guide the formation of the other three through judiciously selected C−C bond formation reactions. Those events, which included a unique Conia‐ene cyclization and a challenging Pauson–Khand reaction, afforded a 17‐step synthesis of the molecule in enantioenriched form.